---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-099837"
form_type: "8-K"
ticker: "RMTG"
cik: "0001760026"
company_name: "Regenerative Medical Technology Group Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:34:51.939048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# RMTG reports Q3 sales up 52% YoY, achieves operational profitability, gross margin 75%

## Summary
- Sales rose 52% YoY to $986,308; gross profit margin reached 75% for Q3 2024.
- Patient procedures revenue surged over 370% YoY, now 37% of revenue versus 12% last year.
- Company achieved operational profitability, defined as revenue minus all operating expenses excluding interest and taxes.
- Dubai clinic expected to launch next week; plans for a manufacturing facility in Cancun to produce exosomes and stem cells.

## SEC filing metadata
- accession: 0001213900-24-099837
- form_type: 8-K
- ticker: RMTG
- cik: 0001760026
- company_name: Regenerative Medical Technology Group Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/0001213900-24-099837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/ea0221755-8k_regenerative.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-099837
- JSON: https://secwatch.observer/filing/0001213900-24-099837.json
- Plain text: https://secwatch.observer/filing/0001213900-24-099837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.